Radiation-Induced Lung Cancers in Murine Models


Radiation therapy is a key weapon in the modern arsenal of cancer treatment. However, this effective treatment comes with risks of its own, and the sheer number of patients that undergo radiation as a part of their therapy regimen is only increasing. As this number increases, so does the incidence of secondary, radiation-induced neoplasias, creating a need for therapeutic agents targeted specifically towards reduction in the incidence of and treatment of these cancers. Development and efficacy testing of these agents requires not only extensive in vitro testing, but also a set of reliable animal models to accurately recreate the complex situations of radiation-induced carcinogenesis. The laboratory mouse Mus musculus remains the most relevant animal model in cancer research due to the molecular and physiological similarities it shares with man, its small size and high rate of breeding in captivity, and its fully sequenced genome. In this work, we review relevant M. musculusinbred and F1 hybrid animal models, as well as methods of induction of radiation-induced lung cancers. Associated molecular pathologies are also included.

Share and Cite:

Rivina, L. , Davoren, M. and Schiestl, R. (2014) Radiation-Induced Lung Cancers in Murine Models. Advances in Lung Cancer, 3, 38-44. doi: 10.4236/alc.2014.32006.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Howlader, N., Noone, A.M., Krapcho, M., Neyman, N., Aminou, R., Altekruse, S.F., Kosary, C.L., Ruhl, J., Tatalovich, Z., Cho, H., Mariotto, A., Eisner, M.P., Lewis, D.R., Chen, H.S., Feuer, E.J. and Cronin, K.A. (2012) SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). National Cancer Institute, Bethesda.
[2] Hall, E.J. and Giaccia, A.J. (2012) Radiobiology for the Radiologist. 7th Edition, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia.
[3] de Arruda, F.F., Puri, D.R., Zhung, J., Narayana, A., Wolden, S., Hunt, M., Stambuk, H., Pfister, D., Kraus, D., Shaha, A., et al. (2006) Intensity-Modulated Radiation Therapy for the Treatment of Oropharyngeal Carcinoma: The Memorial Sloan-Kettering Cancer Center Experience. International Journal of Radiation Oncology, Biology, Physics, 64, 363-373.
[4] Zelefsky, M.J., Fuks, Z. and Leibel, S.A. (2002) Intensity-Modulated Radiation Therapy for Prostate Cancer. Seminars in Radiation Oncology, 12, 229-237. http://dx.doi.org/10.1053/srao.2002.00000
[5] Kim, K., Damoiseaux, R., Norris, A.J., Rivina, L., Bradley, K., Jung, M.E., Gatti, R.A., Schiestl, R.H. and McBride, W.H. (2011) High Throughput Screening of Small Molecule Libraries for Modifiers of Radiation Responses. International Journal of Radiation Biology, 87, 839-845.
[6] Rubin, P. (2008) Late Effects of Cancer Treatment on Normal Tissues: CURED I, LENT. Springer, Berlin, New York. http://dx.doi.org/10.1007/978-3-540-49070-8
[7] Ryan, J.L., Krishnan, S., Movsas, B., Coleman, C.N., Vikram, B. and Yoo, S.S. (2011) Decreasing the Adverse Effects of Cancer Therapy: An NCI Workshop on the Preclinical Development of Radiation Injury Mitigators/Protectors. Radiation Research, 176, 688-691. http://dx.doi.org/10.1667/RR2704.1
[8] Williams, J.P., Brown, S.L., Georges, G.E., Hauer-Jensen, M., Hill, R.P., Huser, A.K., Kirsch, D.G., Macvittie, T.J., Mason, K.A., Medhora, M.M., et al. (2010) Animal Models for Medical Countermeasures to Radiation Exposure. Radiation Research, 173, 557-578. http://dx.doi.org/10.1667/RR1880.1
[9] Jackson, E.L., Willis, N., Mercer, K., Bronson, R.T., Crowley, D., Montoya, R., Jacks, T. and Tuveson, D.A. (2001) Analysis of Lung Tumor Initiation and Progression Using Conditional Expression of Oncogenic K-Ras. Genes & Development, 15, 3243-3248. http://dx.doi.org/10.1101/gad.943001
[10] Frese, K.K. and Tuveson, D.A. (2007) Maximizing Mouse Cancer Models. Nature Reviews Cancer, 7, 645-658. http://dx.doi.org/10.1038/nrc2192
[11] Carbone, D. (1992) Smoking and Cancer. The American Journal of Medicine, 93, 13S-17S.
[12] Coggle, J.E. (1991) The Role of Animal Models in Radiation Lung Carcinogenesis. Radiation and Environmental Biophysics, 30, 239-241. http://dx.doi.org/10.1007/BF01226628
[13] Darby, S.C., Doll, R., Gill, S.K. and Smith, P.G. (1987) Long Term Mortality after a Single Treatment Course with X-Rays in Patients Treated for Ankylosing Spondylitis. British Journal of Cancer, 55, 179-190. http://dx.doi.org/10.1038/bjc.1987.35
[14] Fajardo, L.F., Berthrong, M. and Anderson, R.E. (2001) Radiation Pathology. Oxford University Press, New York.
[15] Griem, M.L., Kleinerman, R.A., Boice Jr., J.D., Stovall, M., Shefner, D. and Lubin, J.H. (1994) Cancer Following Radiotherapy for Peptic Ulcer. Journal of the National Cancer Institute, 86, 842-849. http://dx.doi.org/10.1093/jnci/86.11.842
[16] Egawa, H., Furukawa, K., Preston, D., Funamoto, S., Yonehara, S., Matsuo, T., Tokuoka, S., Suyama, A., Ozasa, K., Kodama, K., et al. (2012) Radiation and Smoking Effects on Lung Cancer Incidence by Histological Types among Atomic Bomb Survivors. Radiation Research, 178, 191-201.
[17] Preston, D.L., Ron, E., Tokuoka, S., Funamoto, S., Nishi, N., Soda, M., Mabuchi, K. and Kodama, K. (2007) Solid Cancer Incidence in Atomic Bomb Survivors: 1958-1998. Radiation Research, 168, 1-64. http://dx.doi.org/10.1667/RR0763.1
[18] Travis, L.B. (2002) Therapy-Associated Solid Tumors. Acta Oncologica, 41, 323-333.
[19] Travis, L.B., Curtis, R.E. and Boice Jr., J.D. (1996) Late Effects of Treatment for Childhood Hodgkin’s Disease. The New England Journal of Medicine, 335, 352-353.
[20] Travis, L.B., Gospodarowicz, M., Curtis, R.E., Clarke, E.A., Andersson, M., Glimelius, B., Joensuu, T., Lynch, C.F., van Leeuwen, F.E., Holowaty, E., et al. (2002) Lung Cancer Following Chemotherapy and Radiotherapy for Hodgkin’s Disease. Journal of the National Cancer Institute, 94, 182-192.
[21] Kirova, Y.M., Gambotti, L., De Rycke, Y., Vilcoq, J.R., Asselain, B. and Fourquet, A. (2007) Risk of Second Malignancies after Adjuvant Radiotherapy for Breast Cancer: A Large-Scale, Single-Institution Review. International Journal of Radiation Oncology, Biology, Physics, 68, 359-363.
[22] Prochazka, M., Granath, F., Ekbom, A., Shields, P.G. and Hall, P. (2002) Lung Cancer Risks in Women with Previous Breast Cancer. European Journal of Cancer, 38, 1520-1525.
[23] Coggle, J.E., Lambert, B.E. and Moores, S.R. (1986) Radiation Effects in the Lung. Environmental Health Perspectives, 70, 261-291. http://dx.doi.org/10.1289/ehp.8670261
[24] Endoh, D., Suzuki, A., Kuwabara, M., Satoh, H. and Sato, F. (1987) Circadian Variation in Lung Tumor Induction with X-Rays in Mice. Journal of Radiation Research, 28, 186-189.
[25] Hashimoto, N., Endoh, D., Kuwabara, M., Satoh, H. and Sato, F. (1994) Induction of Lung Tumors in C3H Strain Mice after Single or Fractionated Irradiation with X-Rays. The Journal of Veterinary Medical Science/The Japanese Society of Veterinary Science, 56, 493-498.
[26] Hashimoto, N., Endoh, D., Kuwabara, M., Satoh, H. and Sato, F. (1990) Dose and Dose-Splitting Effects of X-Rays on Lung Tumour Induction in Mice. International Journal of Radiation Biology, 58, 351-360. http://dx.doi.org/10.1080/09553009014551681
[27] Focan, C. (2002) Chronobiological Concepts Underlying the Chronotherapy of Human Lung Cancer. Chronobiology International, 19, 253-273. http://dx.doi.org/10.1081/CBI-120002601
[28] Ullrich, R.L., Jernigan, M.C. and Adams, L.M. (1979) Induction of Lung Tumors in RFM Mice after Localized Exposures to X Rays or Neutrons. Radiation Research, 80, 464-473.
[29] Yuhas, J.M. and Walker, A.E. (1973) Exposure-Response Curve for Radiation-Induced Lung Tumors in the Mouse. Radiation Research, 54, 261-273. http://dx.doi.org/10.2307/3573704
[30] Ullrich, R.L. (1983) Tumor Induction in BALB/c Female Mice after Fission Neutron or Gamma Irradiation. Radiation Research, 93, 506-515. http://dx.doi.org/10.2307/3576029
[31] Ullrich, R.L., Jernigan, M.C., Satterfield, L.C. and Bowles, N.D. (1987) Radiation Carcinogenesis: Time-Dose Relationships. Radiation Research, 111, 179-184. http://dx.doi.org/10.2307/3577031
[32] Vojtek, A.B. and Der, C.J. (1998) Increasing Complexity of the Ras Signaling Pathway. The Journal of Biological Chemistry, 273, 19925-19928. http://dx.doi.org/10.1074/jbc.273.32.19925
[33] Grahn, D., Lombard, L.S. and Carnes, B.A. (1992) The Comparative Tumorigenic Effects of Fission Neutrons and Cobalt-60 Gamma Rays in the B6CF1 Mouse. Radiation Research, 129, 19-36.
[34] Zhang, Y. and Woloschak, G.E. (1997) Rb and p53 Gene Deletions in Lung Adenocarcinomas from Irradiated and Control Mice. Radiation Research, 148, 81-89. http://dx.doi.org/10.2307/3579541
[35] Zhang, Y. and Woloschak, G.E. (1998) Detection of Codon 12 Point Mutations of the K-Ras Gene from Mouse Lung Adenocarcinoma by “Enriched” PCR. International Journal of Radiation Biology, 74, 43-51. http://dx.doi.org/10.1080/095530098141717
[36] Salgia, R. and Skarin, A.T. (1998) Molecular Abnormalities in Lung Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 16, 1207-1217.
[37] Sekido, Y., Fong, K.M. and Minna, J.D. (1998) Progress in Understanding the Molecular Pathogenesis of Human Lung Cancer. Biochimica et Biophysica Acta, 1378, F21-F59.
[38] Tuveson, D.A. and Jacks, T. (1999) Modeling Human Lung Cancer in Mice: Similarities and Shortcomings. Oncogene, 18, 5318-5324. http://dx.doi.org/10.1038/sj.onc.1203107
[39] D’Amico, D., Carbone, D., Mitsudomi, T., Nau, M., Fedorko, J., Russell, E., Johnson, B., Buchhagen, D., Bodner, S., Phelps, R., et al. (1992) High Frequency of Somatically Acquired p53 Mutations in Small-Cell Lung Cancer Cell Lines and Tumors. Oncogene, 7, 339-346.
[40] Hensel, C.H., Xiang, R.H., Sakaguchi, A.Y. and Naylor, S.L. (1991) Use of the Single Strand Conformation Polymorphism Technique and PCR to Detect p53 Gene Mutations in Small Cell Lung Cancer. Oncogene, 6, 1067-1071.
[41] Sameshima, Y., Matsuno, Y., Hirohashi, S., Shimosato, Y., Mizoguchi, H., Sugimura, T., Terada, M. and Yokota, J. (1992) Alterations of the p53 Gene Are Common and Critical Events for the Maintenance of Malignant Phenotypes in Small-Cell Lung Carcinoma. Oncogene, 7, 451-457.
[42] Takahashi, T., Takahashi, T., Suzuki, H., Hida, T., Sekido, Y., Ariyoshi, Y. and Ueda, R. (1991) The p53 Gene Is Very Frequently Mutated in Small-Cell Lung Cancer with a Distinct Nucleotide Substitution Pattern. Oncogene, 6, 1775-1778.
[43] Olsson, A.Y., Feber, A., Edwards, S., Te Poele, R., Giddings, I., Merson, S. and Cooper, C.S. (2007) Role of E2F3 Expression in Modulating Cellular Proliferation Rate in Human Bladder and Prostate Cancer Cells. Oncogene, 26, 1028-1037. http://dx.doi.org/10.1038/sj.onc.1209854
[44] Sherr, C.J. and McCormick, F. (2002) The RB and p53 Pathways in Cancer. Cancer Cell, 2, 103-112. http://dx.doi.org/10.1016/S1535-6108(02)00102-2
[45] Califano, R., Landi, L. and Cappuzzo, F. (2012) Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer. Drugs, 72, 28-36. http://dx.doi.org/10.2165/1163012-S0-000000000-00000
[46] Bongiorno, P.F., Whyte, R.I., Lesser, E.J., Moore, J.H., Orringer, M.B. and Beer, D.G. (1994) Alterations of K-Ras, p53, and erbB-2/neu in Human Lung Adenocarcinomas. The Journal of Thoracic and Cardiovascular Surgery, 107, 590-595.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.